Congenital heart diseases (CHDs) are the most common cause of all birth defects and account for nearly 25% of all major congenital anomalies leading to mortality in the first year of life. Extracardiac anomalies including urogenital aberrations are present in ∼30% of all cases. Here, we present a rare case of a 46,XY patient with CHD associated with ambiguous genitalia consisting of a clitoris-like phallus and a bifid scrotum. Exome sequencing revealed novel homozygous mutations in the FGFR1 and STARD3 genes that may be associated with the phenotype.

Keywords:
FGFR1, STARD3, Ambiguous external genitalia, Congenital heart disease, Disorders of sex development
1.
Abu-Issa R, Smyth G, Smoak I, Yamamura K, Meyers EN: Fgf8 is required for pharyngeal arch and cardiovascular development in the mouse. Development 129:4613-25 (2002).
2.
Alpy F, Tomasetto C: MLN64 and MENTHO, two mediators of endosomal cholesterol transport. Biochem Soc Trans 34:343-345 (2006).
3.
Bassili A, Mokhtar SA, Dabous NI, Zaher SR, Mokhtar MM, Zaki A: Congenital heart disease among school children in Alexandria, Egypt: an overview on prevalence and relative frequencies. J Trop Pediatr 46:357-362 (2000).
4.
Beiman M, Shilo BZ, Volk T: Heartless, a Drosophila FGF receptor homolog, is essential for cell migration and establishment of several mesodermal lineages. Genes Dev 10:2993-3002 (1996).
5.
Bos JM, Poley RN, Ny M, Tester DJ, Xu X, et al: Genotype-phenotype relationships involving hypertrophic cardiomyopathy-associated mutations in titin, muscle LIM protein, and telethonin. Mol Genet Metab 88:78-85 (2006).
6.
Brancati F, D'Avanzo MG, Digilio MC, Sarkozy A, Biondi M, et al: KBG syndrome in a cohort of Italian patients. Am J Med Genet A 131:144-149 (2004).
7.
Chen GJ, Forough R: Fibroblast growth factors, fibroblast growth factor receptors, diseases, and drugs. Recent Pat Cardiovasc Drug Discov 1:211-224 (2006).
8.
Clark BJ, Wells J, King SR, Stocco DM: The purification, cloning, and expression of a novel luteinizing hormone-induced mitochondrial protein in MA-10 mouse Leydig tumor cells. Characterization of the steroidogenic acute regulatory protein (StAR). J Biol Chem 269:28314-28322 (1994).
9.
Cortez AB, Galindo A, Arensman FW, Van Dop C: Congenital heart disease associated with sporadic Kallmann syndrome. Am J Med Genet 46:551-554 (1993).
10.
Dodé C, Levilliers J, Dupont JM, De Paepe A, Le Dû N, et al: Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome. Nat Genet 33:463-465 (2003).
11.
Dodé C, Fouveaut C, Mortier G, Janssens S, Bertherat J, et al: Novel FGFR1 sequence variants in Kallmann syndrome, and genetic evidence that the FGFR1c isoform is required in olfactory bulb and palate morphogenesis. Hum Mutat 28:97-98 (2007).
12.
Frias JL: Genetic issues of congenital heart defects, in Gessner IH, Victrorica BE (eds): Pediatric Cardiology, pp. 237-242 (Saunders, Philadelphia 1993).
13.
Gregorio CC, Trombitás K, Centner T, Kolmerer B, Stier G, et al: The NH2 terminus of titin spans the Z-disc: its interaction with a novel 19-kD ligand (T-cap) is required for sarcomeric integrity. J Cell Biol 143:1013-1027 (1998).
14.
Güçer S, Ince T, Kale G, Akçören Z, Ozkutlu S, et al: Noncardiac malformations in congenital heart disease: a retrospective analysis of 305 pediatric autopies. Turk J Pediatr 47:159-166 (2005).
15.
Hughes IA: Disorders of sex development: a new definition and classification. Best Pract Res Clin Endocrinol Metab 22:119-134 (2008).
16.
Khalifa M, Stein J, Grau L, Nelson V, Meck J, et al: Partial deletion of ANKRD11 results in the KBG phenotype distinct from the 16q24.3 microdeletion syndrome. Am J Med Genet A 161A:835-840 (2013).
17.
Knöll R, Hoshijima M, Hoffman HM, Person V, Lorenzen-Schmidt I, et al: The cardiac mechanical stretch sensor machinery involves a Z disc complex that is defective in a subset of human dilated cardiomyopathy. Cell 111:943-955 (2002).
18.
Levy CM, Knudtzon J: Kallmann syndrome in two sisters with other developmental anomalies also affecting their father. Clin Genet 43:51-53 (1993).
19.
Lin D, Sugawara T, Strauss JF 3rd, Clark BJ, Stocco DM, et al: Role of steroidogenic acute regulatory protein in adrenal and gonadal steroidogenesis. Science 267:1828-1831 (1995).
20.
Marguerie A, Bajolle F, Zaffran S, Brown NA, Dickson C, et al: Congenital heart defects in Fgfr2-IIIb and Fgf10 mutant mice. Cardiovasc Res 71:50-60 (2006).
21.
Mazen I, El-Ruby M, Kamal R, El-Nekhely I, El-Ghandour M, et al: Screening of genital anomalies in newborns and infants in two Egyptian governorates. Horm Res Paediatr 73:438-442 (2010).
22.
McCulley DJ, Black BL: Transcription factor pathways and congenital heart disease. Curr Top Dev Biol 100:253-277 (2012).
23.
Moog-Lutz C, Tomasetto C, Régnier CH, Wendling C, Lutz Y, et al: MLN64 exhibits homology with the steroidogenic acute regulatory protein (STAR) and is over-expressed in human breast carcinomas. Int J Cancer 71:183-191 (1997).
24.
Nemer M: Genetic insights into normal and abnormal heart development. Cardiovasc Pathol 17:48-54 (2008).
25.
Partanen J, Schwartz L, Rossant J: Opposite phenotypes of hypomorphic and Y766 phosphorylation site mutations reveal a function for Fgfr1 in anteroposterior patterning of mouse embryos. Genes Dev 12:2332-2344 (1998).
26.
Paulozzi LJ: International trends in rates of hypospadias and cryptorchidism. Environ Health Perspect 107:297-302 (1999).
27.
Powers CJ, McLeskey SW, Wellstein A: Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 7:165-197 (2000).
28.
Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M: Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 16:159-178 (2005).
29.
Sato N, Katsumata N, Kagami M, Hasegawa T, Hori N, et al: Clinical assessment and mutation analysis of Kallmann syndrome 1 (KAL1) and fibroblast growth factor receptor 1 (FGFR1, or KAL2) in five families and 18 sporadic patients. J Clin Endocrinol Metab 89:1079-1088 (2004).
30.
Satoh Y, Haraguchi R, Wright TJ, Mansour SL, Partanen J, et al: Regulation of external genitalia development by concerted actions of FGF ligands and FGF receptors. Anat Embryol (Berl) 208:479-486 (2004).
31.
Sax L: How common is intersex? A response to Anne Fausto-Sterling. J Sex Res 39:174-178 (2002).
32.
Simonis N, Migeotte I, Lambert N, Perazzolo C, de Silva DC, et al: FGFR1 mutations cause Hartsfield syndrome, the unique association of holoprosencephaly and ectrodactyly. J Med Genet 50:585-592 (2013).
33.
Thyen U, Lanz K, Holterhus PM, Hiort O: Epidemiology and initial management of ambiguous genitalia at birth in Germany. Hormone Res 66:195-203 (2006).
34.
van der Zanden LF, van Rooij IA, Feitz WF, Vermeulen SH, Kiemeney LA, et al: Genetics of hypospadias: are single-nucleotide polymorphisms in SRD5A2, ESR1, ESR2, ATF3 really associated with the malformation? J Clin Endocrinol Metab 95:2384-2390 (2010).
35.
Villanueva C, Jacobson-Dickman E, Xu C, Manouvrier S, Dwyer AA, et al: Congenital hypogonadotropic hypogonadism with split hand/foot malformation: a clinical entity with a high frequency of FGFR1 mutations. Genet Med 17:651-659 (2015).
36.
Watari H, Arakane F, Moog-Lutz C, Kallen CB, Tomasetto C, et al: MLN64 contains a domain with homology to the steroidogenic acute regulatory protein (StAR) that stimulates steroidogenesis. Proc Natl Acad Sci USA 94:8462-8467 (1997).
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.